Trials / Completed
CompletedNCT01339481
A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept
A Phase 0, Open-Label, Multi-Center, Observational Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 26 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize CD86 receptor occupancy in subjects with rheumatoid arthritis (RA) receiving abatacept.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | abatacept | Intravenous Infusion |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2011-04-20
- Last updated
- 2011-11-29
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01339481. Inclusion in this directory is not an endorsement.